Objective To investigate the clinical effects of Antike capsule given after ultrasound-guided radiofrequency ablation under guidance of real time virtual sonography navigation system in the treatment of patients with hepatic rectal cancer metastases.Methods 74 patients with hepatic rectal cancer metastases were recruited in our hospital between Jan.2012 and Jan.2014,and the participants were randomly divided into two groups.37 patients in control group were treated with ultrasound-guided radiofrequency ablation under guidance of real time virtual sonography navigation system and FOLFOX6 regimen,and another 37 were given Antike orally after radiofrequency ablation and chemotherapy.All patients were followed-up for two years,and the short-term as well as long-term efficacy was evaluated with RECIST and non-progress free survival (PFS).Results The total effective rate was 78.4％ in the observation group,much higher than 62.2％ in the control group (P＜0.05);There was no significant difference as respect to 1 a survival rates in the two groups (89.2％ vs.83.8％,P＞0.0S),while the 2 a survival rate in the observation group was 67.5％,much higher than 54.1％ in the control (P＜0.05);the non-PFS in the observation was 12.4 m (95％ CI 10.0～16.2),much longer than 10.1 m in the control (P＜0.05).Conclusion Antike capsule combined with ultrasound-guided radiofrequency ablation in treatment of patients with hepatic rectal cancer metastases has a good efficacy,and worth to study further in clinical practice.%目的 探讨安替可胶囊联合实时虚拟导航系统引导下射频消融治疗不可切除的直肠癌肝转移患者的临床疗效.方法 2013年1月～ 2014年1月我院收治的74例无法手术切除的直肠癌肝转移患者,37例在实时虚拟导航系统引导下行射频消融和FOLFOX6方案化疗,37例观察组在上述治疗的基础上同时给予安替可胶囊口服治疗.采用实体瘤疗效评价标准评价近期疗效,观察两组无疾病进展生存时间(PFS)和生存率.结果 观察组近期疗效总有效率为78.4％,明显高于对照组的62.2％(P＜0.05);两组1 a生存率分别为89.2％和83.8％,而观察组2 a生存率则显著高于对照组(67.5％对54.1％,P＜0.05);观察组中位PFS为12.4个月(95％可信区间为10.0～16.2),明显长于对照组的10.1个月,差异具有统计学意义(P＜0.05).结论 对外科手术不可切除的直肠癌肝转移患者,在实时虚拟导航系统引导下行射频消融治疗,术后给予安替可胶囊口服,疗效确切,安全性较高.
展开▼
